Form 4: Haemonetics Director Ellen Zane Receives Equity Award

Haemonetics Corporation Director Ellen M. Zane was granted 2,693 restricted stock units, increasing her beneficial ownership to 19,373 shares.

Summary

• Ellen M. Zane, a Director of HAEMONETICS CORP (HAE), acquired 2,693 shares of Common Stock on July 24, 2025.
• The acquisition was in the form of Restricted Stock Units (RSUs) issued under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan.
• These RSUs are scheduled to vest 100% on the first anniversary of the grant date.
• Following this transaction, Ellen M. Zane's total beneficial ownership of Haemonetics Common Stock is 19,373 shares.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The filing reports a routine equity compensation grant to a director, which is a positive for aligning interests but does not indicate significant new operational or financial developments.

Positives

• The grant of restricted stock units to a director aligns management and board interests with those of shareholders, encouraging long-term value creation.
• The transaction was conducted under a Rule 10b5-1 plan, demonstrating a pre-planned and transparent approach to equity compensation.

Future Outlook

The 2,693 restricted stock units granted are expected to vest 100% on the first anniversary of the grant date, which is July 24, 2026, at which point they will convert into shares of the Issuer's common stock.

Industry Context

The granting of equity awards, such as restricted stock units, to directors is a common practice across industries, including the medical technology sector, to incentivize long-term performance and align leadership interests with shareholder value.

Comparison to Industry Standards

• Equity compensation for directors, often in the form of RSUs, is a standard component of compensation packages in publicly traded companies, including those comparable to Haemonetics in the medical device and healthcare technology sectors.
• The use of a Rule 10b5-1 plan for such grants is considered a best practice in corporate governance, enhancing transparency and mitigating concerns about insider trading, similar to practices observed at companies like Medtronic or Baxter International.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of equity compensation from Haemonetics Corporation to Ellen M. Zane, a director of the company, which constitutes a related party transaction as part of her compensation package.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The 2,693 restricted stock units are expected to vest on July 24, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director, which is a standard practice for aligning interests. It does not contain new material information that would significantly alter the investment thesis or warrant a change in recommendation for Haemonetics stock.

Keywords

Haemonetics, HAE, Director, Equity Compensation, Restricted Stock Units, RSU, Insider Transaction, Form 4, Corporate Governance